Department of Restorative Dentistry, School of Dentistry, University of São Paulo, São Paulo, Brazil.
Department of Pediatric Dentistry, School of Dentistry, University of São Paulo, São Paulo, Brazil.
J Oral Rehabil. 2022 Jan;49(1):62-70. doi: 10.1111/joor.13270. Epub 2021 Nov 2.
Dentin hypersensitivity (DH) is a common problem in the population that can have a significant impact on the quality of life of those who suffer from the condition.
Compare the efficacy of two treatments for DH: Ca/PO /F varnish (Clinpro White Varnish) and ionomeric sealant (IS) (Clinpro XT Varnish) with a placebo.
Participants (121) with at least one tooth with visual analogue scale (VAS) score of 4 and above were randomly and blindly allocated to the groups. Treatments were performed by a trained researcher. DH was evaluated by another blind researcher after the treatment and after 1 week, 4 weeks, 3 months and 6 months. After 4 weeks, placebo received the DH treatment with IS; thus, the participants were not assessed after 3 and 6 months. Primary outcome was DH reduction after 4 weeks. Differences in VAS scores in the other time intervals and entire values of VAS were considered secondary outcomes. Comparisons were made among the groups (α = 0.05).
IS showed the highest VAS value difference between baseline and 4 weeks (mean ± SD: 3.7 ± 2.2), differing significantly from placebo (2.3 ± 1.7) and Ca/PO4/F varnish (2.6 ± 2.0). Ca/PO4 /F varnish did not differ from placebo. In all time intervals, VAS values of all groups were significantly lower than the baseline value, without differences among groups. For the long-term differences in VAS values (3 and 6 months), the IS exhibited significantly higher values than Ca/PO4 /F varnish.
The IS was the most efficacious product for reducing DH, whereas Ca/PO4 /F varnish did not differ from placebo. Registered in ClinicalTrials.gov (NCT04591444).
牙本质敏感(DH)是人群中常见的问题,会对患病者的生活质量产生重大影响。
比较两种治疗 DH 的疗效:Ca/PO /F 清漆(Clinpro White Varnish)和离聚物密封剂(IS)(Clinpro XT Varnish)与安慰剂。
将至少有一颗牙齿视觉模拟量表(VAS)评分≥4 的参与者(121 名)随机和盲法分配到各组。由一名训练有素的研究人员进行治疗。治疗后和 1 周、4 周、3 个月和 6 个月后,由另一名盲法研究人员评估 DH。4 周后,安慰剂组接受 IS 的 DH 治疗;因此,参与者在 3 个月和 6 个月后未进行评估。主要结局为 4 周时 DH 减少。其他时间间隔的 VAS 评分差异和 VAS 总数值为次要结局。在组间进行比较(α=0.05)。
IS 在基线和 4 周之间显示出最大的 VAS 值差异(平均值±标准差:3.7±2.2),与安慰剂(2.3±1.7)和 Ca/PO4/F 清漆(2.6±2.0)相比,差异有统计学意义。Ca/PO4/F 清漆与安慰剂无差异。在所有时间间隔内,所有组的 VAS 值均显著低于基线值,组间无差异。对于 VAS 值的长期差异(3 个月和 6 个月),IS 表现出显著高于 Ca/PO4/F 清漆的值。
IS 是减少 DH 最有效的产品,而 Ca/PO4/F 清漆与安慰剂无差异。在 ClinicalTrials.gov(NCT04591444)注册。